ABSI Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Nanoviricides's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 280.12%. Given that Nanoviricides has higher upside potential than Absci, analysts believe Nanoviricides is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Absci quarterly revenues are $1.2M, which are larger than Nanoviricides quarterly revenues of --. Absci's net income of -$26.3M is lower than Nanoviricides's net income of -$2.2M. Notably, Absci's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Oragenics's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Absci, analysts believe Oragenics is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Absci quarterly revenues are $1.2M, which are larger than Oragenics quarterly revenues of --. Absci's net income of -$26.3M is lower than Oragenics's net income of -$2.2M. Notably, Absci's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -2234.61% compared to Absci's net margin of -1366.49%. Absci's return on equity of -51.63% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.43 which suggests that it could grow by 69.22%. Given that Absci has higher upside potential than Recursion Pharmaceuticals, analysts believe Absci is more attractive than Recursion Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $1.2M, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Absci's net income of -$26.3M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Absci's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 23.19x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Theriva Biologics's return on equity of --.

Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Absci, analysts believe Theriva Biologics is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Absci quarterly revenues are $1.2M, which are larger than Theriva Biologics quarterly revenues of --. Absci's net income of -$26.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Absci's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.